We are passionate about finding the right therapeutic solution for patients
We truly believe that medicines should be tailored, that’s why our products are designed specifically to take into account patients’ needs.
We are passionate about finding the right therapeutic solution for patients
We truly believe that medicines should be tailored, that’s why our products are designed specifically to take into account patients’ needs.
Science
Our expertise is the ability to design, develop and take new medicines for difficult-to-treat patient groups through to regulatory approval and beyond
We identify unmet needs for off-patent products for specific populations such as children and the elderly. We develop new formulations or routes of delivery of existing medicines to create novel products.
We have a strong track record in the research and development of innovative medicines and drug delivery systems designed specifically to provide optimum dosage taking into account the pharmacodynamics and pharmacokinetics of children and the elderly.
Our clinical programmes are significantly de-risked compared to traditional biotech and pharma models by reformulating existing, approved products with proven safety and efficacy profiles, resulting in specially designed medicines to maximise efficacy and ease of use and thereby improve adherence and disease management.
To date, we have conducted:
10
Clinical studies
6
In children, one of which included neonates and infants
4
In adults
These studies comprised efficacy, safety, and/or pharmacokinetics and include the following types: emergency department, intensive care and other hospital settings, post authorisation safety, CRO site studies, single centre and multicentre/multi-country studies.
Focus
We specialise in developing age-specific medicines that enable easier and more accurate treatment regimens
Medicines are usually designed for adults with the dose adjusted for children or the elderly. We believe each of these markets have specific needs that are not met by current treatment options and have the potential to cause unintended harm.
Children are not small adults. With many products not tested in children, off-label prescribing leads to the guessing of appropriate dosages and potential adverse effects, with difficult or unpleasant treatment regimens an issue. European Commission legislation secures 10 years data protection for medicines developed exclusively for use in the paediatric population.
For geriatric patients and people with chronic illnesses, adherence is the big issue due to physical difficulties such as swallowing or injection and mental capacity issues such as remembering treatment or keeping track of time, which are exacerbated by a lack of monitoring, financial constraints, mobility and complicated instructions.These patients need treatments that are easy to take and adjusted for their physiology in a simple regimen.